Idelalisib

Drug Overview

Idelalisib, sold under the US brand name Zydelig, is a first-in-class oral Targeted Therapy that was the first drug ever approved to specifically block a protein called PI3K-delta — a key survival engine in blood cancer cells. It targets the phosphoinositide 3-kinase p110 isoform δ (PI3Kδ) with high potency and selectivity, an isoform that is hyperactivated in B-cell malignancies and plays a pivotal role in the B-cell receptor pathway.

Idelalisib marked a turning point in the treatment of relapsed blood cancers by proving that blocking a single, precisely chosen molecular target — rather than using broad chemotherapy — could produce powerful responses in previously difficult-to-treat patient populations. Physicians should note an important regulatory update: the approval for follicular lymphoma and small lymphocytic lymphoma was voluntarily withdrawn by the manufacturer in May 2022 after failing to complete post-marketing confirmatory studies required by the FDA.

• Generic Name: Idelalisib
• US Brand Name: Zydelig (Gilead Sciences)
• Drug Class: PI3K-Delta Inhibitor / Kinase Inhibitor / Targeted Therapy
• Route of Administration: Oral (tablet, taken by mouth)
• FDA Approval Status: Approved on July 23, 2014, for relapsed CLL in combination with rituximab in patients for whom rituximab alone would be appropriate due to comorbidities. FDA approvals for follicular lymphoma and SLL were voluntarily withdrawn in May 2022. A Risk Evaluation and Mitigation Strategy (REMS) program is in place.

What Is It and How Does It Work? (Mechanism of Action)

In healthy B-cells, the B-Cell Receptor (BCR) pathway controls normal cell growth. In blood cancers like CLL, this pathway is permanently switched on, sending non-stop survival signals to cancer cells. A key amplifier of this pathway is the enzyme PI3K-delta — a protein almost exclusively expressed in blood cells, making it an ideal precision target.

Selective inhibition of PI3Kδ acts directly on lymphoma cells, reducing Akt phosphorylation and limiting activation of the mTOR/Akt and NF-κB pathways, leading to apoptosis through a caspase-dependent mechanism. Here is the step-by-step molecular process:

Competitive ATP Blocking: Idelalisib is a competitive inhibitor of the ATP binding site of the PI3Kδ catalytic domain. By occupying this site, idelalisib cuts off the energy supply that PI3Kδ needs to fire survival signals — effectively silencing the pathway at its source.

Disrupting the Tumor Microenvironment: Idelalisib also blocks adhesion of tumor cells to supporting stromal cells and reduces secretion of chemokines CCL3 and CCL4, which normally act as distress signals that recruit protective cells to surround and shield the tumor. By cutting off these signals, idelalisib exposes cancer cells and removes their protective environment.

Downstream Signal Collapse: With PI3Kδ blocked, the critical downstream proteins AKT and mTOR — which tell cancer cells to survive, multiply, and resist treatment — are deactivated. This cascade collapse ultimately forces the cancer cell to undergo programmed cell death.

FDA Approved Clinical Indications

Oncological Uses (Current FDA-Approved Indication):

• Relapsed Chronic Lymphocytic Leukemia (CLL) in combination with rituximab, in adult patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities

Withdrawn Indications (No Longer FDA-Approved):

• Relapsed follicular lymphoma and relapsed small lymphocytic lymphoma — both voluntarily withdrawn in May 2022

Non-Oncological Uses:

• There are no approved non-oncological indications for idelalisib.

Dosage and Administration Protocols

The recommended starting dose of idelalisib is 150 mg orally with or without food twice daily. Treatment continues until disease progression or unacceptable toxicity. Tablets should be swallowed whole and must never be crushed or split.

Clinical Efficacy and Research Results

Idelalisib’s approval in CLL was built on strong phase III evidence. In the pivotal Study 116 trial (NCT01539512), 220 patients with relapsed CLL who were unsuitable for cytotoxic therapy were randomized to idelalisib plus rituximab or placebo plus rituximab. The median PFS was 10.7 months for patients treated with idelalisib and rituximab compared with 5.5 months with rituximab and placebo. The ORR with idelalisib was 77% versus 15% with placebo (p < 0.0001). Of evaluable patients, 92% treated with idelalisib experienced a greater than 50% reduction in lymph node size compared with 6% with placebo (p < 0.0001).

In the DELTA trial, which supported the now-withdrawn indications, results showed 54% of participants with relapsed follicular lymphoma and 58% with SLL experienced an objective response rate, establishing meaningful single-agent activity in these populations despite the subsequent regulatory withdrawal due to unresolved survival concerns.

Notably, the voluntary withdrawal of the FL and SLL indications in 2022 was part of a broader industry trend — coinciding with the withdrawal of every other PI3K inhibitor for follicular lymphoma: duvelisib in December 2021, umbralisib in January 2022, and copanlisib in November 2023, attributed to a possibly detrimental effect on survival seen in multiple studies of this drug class, likely due to toxic side effects.

Safety Profile and Side Effects

Black Box Warning: Idelalisib carries a Boxed Warning for fatal and serious liver toxicity, diarrhea, colitis, pneumonitis, and intestinal perforation. Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. A REMS program is mandatory.

Common Side Effects (>10%):

• Diarrhea/Colitis — the median time to onset of any-grade diarrhea or colitis was 1.9 months; severe diarrhea responds poorly to antimotility agents and typically requires idelalisib interruption and corticosteroids
• Hepatotoxicity — liver enzyme elevations occur frequently; monitor LFTs every 2 weeks during the first 6 months
• Fatigue and Nausea — generally low grade and manageable
• Neutropenia — low white blood cell counts increase infection risk; monitor CBC regularly

Serious Adverse Events:

• Pneumonitis: Pneumonitis occurred in 3% of idelalisib-treated patients across clinical trials, with fatal cases reported; discontinue immediately if pneumonitis is suspected and initiate corticosteroids
• Serious Infections: In March 2016, Gilead alerted healthcare providers about decreased overall survival and increased risk of serious infections in patients treated with idelalisib, leading to the stoppage of six clinical trials
• Intestinal Perforation: Rare but life-threatening; patients should report severe abdominal pain immediately

Management Strategies:

• For hepatotoxicity: monitor LFTs every 2 weeks for the first 6 months; hold for ALT/AST > 5× ULN and discontinue permanently if > 20× ULN
• For severe diarrhea: interrupt idelalisib immediately; initiate systemic corticosteroids; do not use anti-diarrheal agents as sole management
• For pneumonitis: stop idelalisib permanently; begin high-dose corticosteroids without delay

Research Areas

Although idelalisib’s clinical use has narrowed following the 2022 withdrawal of its lymphoma indications, scientific interest in PI3Kδ inhibition remains active. Researchers are studying next-generation PI3Kδ inhibitors with improved safety profiles, informed by lessons learned from idelalisib’s toxicity data. Combination strategies pairing idelalisib with novel immunotherapy agents — including anti-PD-1 checkpoint inhibitors and BTK inhibitors — are under investigation for relapsed CLL, with the goal of improving depth of response while managing immune-mediated toxicities through careful patient selection and prophylactic support measures.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• Liver function tests (LFTs) — mandatory baseline assessment
• Complete blood count (CBC) with differential
• Pulmonary function assessment and baseline chest imaging
• Cytomegalovirus (CMV) screening and hepatitis B serology
• Pregnancy test for women of childbearing age

Precautions During Treatment:

• LFTs must be monitored every 2 weeks during the first 6 months; monthly thereafter
• All patients should receive prophylactic medication against Pneumocystis jirovecii pneumonia (PJP), continued for up to 6 months after idelalisib is stopped
• Avoid all strong CYP3A4 inhibitors and inducers — these significantly alter idelalisib blood levels

Do’s and Don’ts:

• DO take idelalisib at the same times each day, with or without food
• DO report any new or worsening diarrhea, abdominal pain, or shortness of breath immediately
• DO attend all scheduled blood and liver function monitoring appointments
• DON’T ignore fever — any temperature above 38°C (100.4°F) requires urgent medical evaluation
• DON’T breastfeed during treatment — idelalisib may harm a nursing infant
• DON’T take any new medications or supplements without first consulting your oncologist

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Idelalisib (Zydelig) is a prescription medication that must only be used under the direct supervision of a qualified oncologist. Its FDA approvals for follicular lymphoma and small lymphocytic lymphoma were voluntarily withdrawn in May 2022; it currently remains FDA-approved only for relapsed CLL in combination with rituximab. Individual treatment decisions must always be made in consultation with a licensed healthcare professional with full knowledge of the patient’s complete medical history. This content does not replace the official FDA-approved prescribing information or professional medical judgment.